BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scheen AJ. Could metformin modulate cardiovascular outcomes differently with DPP-4 inhibitors compared with SGLT2 inhibitors? Diabetes Metab 2021;47:101209. [PMID: 33189895 DOI: 10.1016/j.diabet.2020.11.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Scheen AJ. Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: a comprehensive review ranging from sulphonylureas to SGLT2 inhibitors. Diabetes & Metabolism 2022. [DOI: 10.1016/j.diabet.2022.101405] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Chen SY, Kong XQ, Zhang KF, Luo S, Wang F, Zhang JJ. DPP4 as a Potential Candidate in Cardiovascular Disease. J Inflamm Res 2022;15:5457-69. [PMID: 36147690 DOI: 10.2147/JIR.S380285] [Reference Citation Analysis]
3 Scheen AJ. Antidiabetic agents and risk of atrial fibrillation/flutter: a comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes & Metabolism 2022. [DOI: 10.1016/j.diabet.2022.101390] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Wang D, Liu J, Zhou L, Zhang Q, Li M, Xiao X. Effects of Oral Glucose-Lowering Agents on Gut Microbiota and Microbial Metabolites. Front Endocrinol 2022;13:905171. [DOI: 10.3389/fendo.2022.905171] [Reference Citation Analysis]